|Bid||0.00 x 1100|
|Ask||0.00 x 1800|
|Day's range||50.44 - 51.76|
|52-week range||45.17 - 54.26|
|Beta (5Y monthly)||0.48|
|PE ratio (TTM)||18.52|
|Forward dividend & yield||1.93 (3.75%)|
|Ex-dividend date||03 May 2021|
|1y target est||63.63|
Regeneron (REGN) is expected to maintain momentum on the back of a solid and diverse portfolio. The promising pipeline also sets the stage for further growth.
Glaxo (GSK) rejects a $68 billion buyout offer for its consumer healthcare unit from Unilever. FDA updates for Pfizer (PFE), AbbVie (ABBV) and AstraZeneca (AZN) grab headlines.
Sanofi's (SNY) PRIME is the second successful study on Dupixent for the prurigo nodularis indication.